新华医疗
(600587)
| 流通市值：89.96亿 | | | 总市值：94.32亿 |
| 流通股本：4.45亿 | | | 总股本：4.67亿 |
| 报告期 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 10,011,868,423.4 | 7,316,820,996.26 | 5,072,990,454.71 | 2,438,890,277.93 |
| 营业收入 | 10,011,868,423.4 | 7,316,820,996.26 | 5,072,990,454.71 | 2,438,890,277.93 |
| 二、营业总成本 | 9,238,989,522.38 | 6,678,817,577.94 | 4,581,915,118.8 | 2,215,993,908.16 |
| 营业成本 | 7,271,306,435.97 | 5,291,249,461.88 | 3,682,737,841.42 | 1,799,527,585.72 |
| 税金及附加 | 76,988,683.09 | 51,551,370.24 | 33,354,007.52 | 14,661,765.48 |
| 销售费用 | 912,683,434.45 | 676,237,949.21 | 439,394,915.93 | 206,355,574.53 |
| 管理费用 | 520,242,394.01 | 351,188,573.97 | 239,155,645.17 | 113,528,277.78 |
| 研发费用 | 443,365,130.09 | 291,314,885.11 | 178,578,508.25 | 73,557,725.07 |
| 财务费用 | 14,403,444.77 | 17,275,337.53 | 8,694,200.51 | 8,362,979.58 |
| 其中:利息费用 | 47,071,823.36 | 39,850,592.28 | 25,259,146.66 | 14,127,183.76 |
| 其中:利息收入 | 29,846,241.93 | 21,287,067.26 | -11,939,714.03 | 4,419,263.22 |
| 加:公允价值变动收益 | 12,536,023.66 | 12,010,986.86 | 39,684,757.06 | 18,316,041.72 |
| 加:投资收益 | 81,117,962.39 | 55,729,290.71 | 30,485,908.95 | 11,029,530.7 |
| 资产处置收益 | 3,754,207.14 | -909,735.39 | -57,618.31 | -57,618.31 |
| 资产减值损失(新) | -47,477,564.31 | -14,938,877.45 | -13,092,418.43 | -3,793,108.81 |
| 信用减值损失(新) | -86,442,521.78 | -11,833,178.66 | -12,086,934.37 | -5,285,224.52 |
| 其他收益 | 20,586,374.43 | 11,300,547.99 | 8,912,506.57 | 2,175,577.71 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 756,953,382.55 | 689,362,452.38 | 544,921,537.38 | 245,281,568.26 |
| 加:营业外收入 | 10,584,775.84 | 6,727,537.22 | 3,577,285.71 | 1,071,163.52 |
| 减:营业外支出 | 28,959,031.16 | 4,592,404.88 | 2,941,373.04 | 10,243,789.37 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 738,579,127.23 | 691,497,584.72 | 545,557,450.05 | 236,108,942.41 |
| 减:所得税费用 | 62,077,744.01 | 85,712,422.67 | 67,970,461.39 | 34,075,975.14 |
| 六、净利润 | 676,501,383.22 | 605,785,162.05 | 477,586,988.66 | 202,032,967.27 |
| 持续经营净利润 | 676,501,383.22 | 605,785,162.05 | 477,586,988.66 | 202,032,967.27 |
| 归属于母公司股东的净利润 | 653,997,275.95 | 578,657,965.69 | 458,690,520.05 | 196,511,980.14 |
| 少数股东损益 | 22,504,107.27 | 27,127,196.36 | 18,896,468.61 | 5,520,987.13 |
| (一)基本每股收益 | 1.43 | 1.29 | 1.03 | 0.46 |
| (二)稀释每股收益 | 1.43 | 1.29 | 1.03 | 0.46 |
| 八、其他综合收益 | 21,899 | - | 4,679,026.66 | - |
| 归属于母公司股东的其他综合收益 | 21,899 | - | 4,679,026.66 | - |
| 九、综合收益总额 | 676,523,282.22 | 605,785,162.05 | 482,266,015.32 | 202,032,967.27 |
| 归属于母公司股东的综合收益总额 | 654,019,174.95 | 578,657,965.69 | 463,369,546.71 | 196,511,980.14 |
| 归属于少数股东的综合收益总额 | 22,504,107.27 | 27,127,196.36 | 18,896,468.61 | 5,520,987.13 |
| 公告日期 | 2024-03-29 | 2023-10-25 | 2023-08-23 | 2023-04-28 |
| 审计意见(境内) | 标准无保留意见 | | | |